Vaccination against cytomegalovirus, the changeling demon

Pediatric Infectious Disease Journal

Volumn 18, Issue 4, 1999, Pages 313-326

  Plotkin, Stanley A ^a,b,c  

^a Pasteur Merieux Connaught   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

Congenital infection; Cytomegalovirus; Glycoprotein B; Prime boost; Towne live virus; Vaccination

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; VIRUS GLYCOPROTEIN;

ACTIVE IMMUNIZATION; ATHEROSCLEROSIS; CELLULAR IMMUNITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; KIDNEY TRANSPLANTATION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VIRUS GENE;

EID: 0032962858     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199904000-00002     Document Type: Review

References (141)

1. Balfour HH Jr. Cytomegalovirus: the troll of transplantation [Editorial]. Arch Intern Med 1979;139:280.
2. Grimm J. Teutonic mythologie. 4th ed. vol. 2:469. New York: Dover Publications, 1877 [Translated by JS Stallybrass].
3. Britt WJ. Vaccines against human cytomegalovirus: time to test. Trends Microbiol 1996;4:34-8.
4. Adler SP. Development and clinical status of cytomegalovirus vaccines. Clin Immunother 1994;2:1-6.
5. Marshall GS. Cytomegalovirus vaccines: two decades of progress. Herpes 1997:20-3.
6. Plotkin SA. Cytomegalovirus vaccine development: past and present. Transplant Proc 1991;23:85-9.
7. Stoll C, Alembik Y, Dott B, et al. Study of Down syndrome in 238 942 consecutive births. Ann Genet 1998;41:44-51.
8. Morton JE, Bundey S, Webb TB, et al. Fragile X syndrome is less common than was previously estimated. J Med Genet 1997;34:1-5.
9. Fowler KB, Stagno S, Pass RF, et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992;326:663-73.
10. Murph JR, Souza IE, Dawson JD. Epidemiology of cytomegalovirus infection: maternal risk factors and molecular analysis of cytomegalovirus strains. Am J Epidemiol 1998;147: 940-7.
11. Mocarski ES. Cytomegalovirus biology and replication. In: Roizman B, Whitley RJ, Lopez C, eds. The human herpesviruses. New York: Raven Press, 1993:173-226.
12. Britt WJ, Mach M. Human cytomegalovirus glycoproteins. Intervirology 1996;39:401-12.
13. Plotkin SA. Cytomegalovirus. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: Saunders, 1999:903-8.
14. Reyburn HT, Mandelboim O, Vales-Gomez M, et al. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997;386:514-7.
15. Hutto C, Little A, Ricks R, et al. Isolation of CMV from toys and hands in a day care center. J Infect Dis 1985;154:527-30.
16. Stagno S, Reynolds D, Pass R. Breast milk and the risk of cytomegalovirus infection. N Engl J Med 1980;302:1073-6.
17. Reynolds D, Stagno S, Hosty TS, et al. Maternal cytomegalovirus excretion and perinatal infection. N Engl J Med 1973;289:1-5.
18. Chandler SH, Holmer KK, Wentworth B, et al. The epidemiology of cytomegaloviral infection in women attending a sexual transmitted disease clinic. J Infect Dis 1985;152:597-605.
19. Coonrod D, Collier AC, Ashley R, et al. Association between cytomegalovirus seroconversion and upper genital tract infection among women attending a sexually transmitted disease clinic: a prospective study. J Infect Dis 1998;177: 1188-93.
20. Yeager AS, Grumet FC, Hafleigh EB, et al. Prevention of transfusion acquired cytomegalovirus infections in newborn infants. J Pediatr 1981;98:281-4.
21. Klemola E, Kaariainen L, von Essen R, et al. Further studies on cytomegalovirus mononucleosis in previously healthy individuals. Acta Med Scand 1967;182:311-22.
22. Rinaldo CR, Black PH, Hirsch MS. Interaction of cytomegalovirus with leucocytes from patients with mononucleosis due to cytomegalovirus. J Infect Dis 1977;136:667-78.
23. Stagno S, Pass RF, Dworsky ME, Alford CA. Congenital and perinatal cytomegalovirus infections. Semin Perinatol 1993; 7:31-42.
24. Nelson CT, Demmler GJ. Cytomegalovirus infection in the pregnant mother, fetus and newborn infant. Infect Perinatol 1997;24:151-60.
25. Demmler GJ. Summary of a workshop or surveillance for congenital cytomegalovirus disease. Rev Infect Dis 1991;13: 315-29.
26. Griffiths PD, Baboonian C. A prospective study of primary cytomegalovirus infection during pregnancy. Br J Obstet Gynaecol 1984;91:307-15.
27. Nankervis GA, Kumar ML, Cox EE, Gold E. A prospective study of maternal cytomegalovirus infection and its effect on the fetus. Am J Obstet Gynecol 1984;149:435-40.
28. Hemmings DG, Kilani R, Nykiforuk C, et al. Permissive cytomegalovirus infection of primary villous term and first trimester trophoblasts. J Virol 1998;72:4970-9.
29. Kutza AS, Muhl E, Hackstein H. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998;26:1076-82.
30. Zaia JA, Forman SJ. Cytomegalovirus infection in the bone marrow transplant recipient. Infect Dis Clin North Am 1995;9:879-900.
31. Chandler SH, Hansfield HH, McDougall JK. Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease. J Infect Dis 1987; 155:655-60.
32. Chou SW. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 1986;314:1418-23.
33. Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995;171:26-32.
34. Fowler KB, Stagno S, Pass RF. Maternal cytomegalovirus immunity and rise of congenital cytomegalovirus infection in future pregnancies [Abstract]. Presented at the meeting of The American Society Pediatric Society and the Society for Pediatric Research, Washington, DC, May 6 to 10, 1996.
35. Grundy JE, Sui SF, Super M, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988;16:132-5.
36. Suwansirikul S, Rao N, Dowling JN, Ho M. Primary and secondary cytomegalovirus infection. Arch Intern Med 1977; 137:1026-9.
37. Stagno S. Cytomegalovirus. In: Remington J, Klein JO, eds. Infectious diseases of the fetus and newborn infant. Philadelphia: Saunders, 1995:312-53.
38. Morgello S, Cho ES, Nielsen S. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: an autopsy study of 30 cases and a review of the literature. Hum Pathol 1987;18:289-97.
39. Studahl M, Ricksten A, Sandberg T, Bergstrom T, Elowson S. Cytomegalovirus encephalitis in four immunocompetent patients. Lancet 1992;340:1045-6.
40. Smith MA, Brennessel DJ. Cytomegalovirus. Infect Dis Clin North Am 1994;8:427-38.
41. Snydman DR, Werner BG, Meissner HC, et al. Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatr Infect Dis J 1995;14:34-40.
42. Werner BG, Snydman DR, Freeman R, et al. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. Transplant Proc 1993;25:1441-3.
43. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314:1006-10.
44. Smiley ML, Wlodaver CG, Grossman RA, et al. The role of pretransplant immunity in protection. Transplantation 1985;40:157-61.
45. Snydman DR, Werner GB, Heinze-Lacy B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317:1049-54.
46. Meyers JD. Prevention of cytomegalovirus infection after marrow transplantation. Rev Infect Dis 1989;11:s1691-705.
47. Steffens HP, Kurtz S, Holtappels R, Reddehase MJ. Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol 1998;72:1797-804.
48. Reddehase MJ, Mutter W, Munch K, Buhring HJ, Koszinowski UH. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 1987;61:3102-8.
49. Koszinowski UH, Del Val M, Reddehase MJ. Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol 1990; 154:189-220.
50. Henson D, Siegel SE, Fuccillo DA, et al. Cytomegalovirus infections during acute childhood leukemia. J Infect Dis 1972;126:469-81.
51. Ho M. Cytomegalovirus: biology and infection. New York: Plenum, 1991.
52. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine: The Zidovudine Epidemiology Study Group. J Infect Dis 1992;166:1223-7.
53. Starr SE, Tolpin MD, Friedman HM, Paucker K, Plotkin SA. Impaired cellular immunity to cytomegalovirus in congenitally infected children and their mothers. J Infect Dis 1979;140:500-5.
54. Gehrz RC, Marker SC, Knorr SO, Kalis JM, Balfour HH Jr. Specific cell-mediated immune defect in active cytomegalovirus infection of young children and their mothers. Lancet 1977;2:844-7.
55. Quinnan GV Jr, Kirmani N, Rook AH. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982;307:7-13.
56. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44.
57. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83:1971-9.
58. Gupta R, Gonczol E, Manning ML, et al. Delayed type hypersensitivity to human cytomegalovirus. J Med Virol 1993;39:109-17.
59. Ada G. Immunology of vaccination. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: Saunders, 1999:28-39.
60. Jonjic S, Pavic I, Polic B, et al. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 1994;179: 1713-7.
61. Minamishima Y, Yoshida EY, Fukunishi R. Murine model for immunoprophylaxis of cytomegalovirus infection: I. Efficacy of immunization. Microbiol Immunol 1978;22:693-700.
62. Rapp M, Messerle M, Lucin P, et al. In vivo protection studies with MCMV glycoproteins gB and gH expressed by vaccinia virus. In: Michelson S, Plotkin SA, eds. Proceedings of the Fourth International Cytomegalovirus Workshop: multidisciplinary approaches to understanding CMV disease, Paris, France, April 19 to 21, 1993. Amsterdam: Excerpts Medica, 1993:327-32.
63. Bia FJ, Griffith BP, Fong CK, Hsiung GD. Cytomegaloviral infections in the guinea pig: experimental models for human disease. Rev Infect Dis 1983;5:177-95.
64. Harrison CJ, Myers MG. Relation of maternal CMV viremia and antibody response to the rate of congenital infection and intrauterine growth retardation. J Med Virol 1990;31: 222-8.
65. Griffith BP, Chen M, Isom HC. Role of primary and secondary maternal viremia in transplacental guinea pig cytomegalovirus transfer. J Virol 1990;64:1991-7.
66. Harrison CJ, Britt WJ, Chapman NM, et al. Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea model. J Infect Dis 1995;172:1-9.
67. Bia FJ, Miller SA, Lucia HL. Vaccination against transplacental cytomegalovirus transmission: vaccine reactivation and efficacy in guinea pigs. J Infect Dis 1984;149:355-62.
68. Stagno S, Pass RF, Dworsky ME, et al. Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N Engl J Med 1982;306:945-9.
69. Plotkin SA, Starr SE, Friedman FM, et al. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 1989; 159:860-5.
70. Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1974;1:1-5.
71. Neff BJ, Weibel RE, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med 1979;160:32-7.
72. Plotkin SA, Furukawa T, Zygraich N, Huygelen C. Candidate cytomegalovirus strain for human vaccination. Infect Immun 1975;12:521-7.
73. Plotkin SA, Eagle H, Hayflick L, et al. Serially cultured animal cells for the preparation of viral vaccines. Science 1969;165:1278-82.
74. Yamane Y, Furukawa T, Plotkin SA. Supernatant virus release as a differentiating marker between low passage and vaccine strains of human cytomegalovirus. Vaccine 1983;1: 23-5.
75. Plotkin SA, Farquhar J, Horberger E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis 1976;134:470-5.
76. Marshall GS, Plotkin SA. Progress toward developing a cytomegalovirus vaccine. Infect Dis Clin North Am 1990;4: 283-98.
77. Quinnan GV Jr, Delery MRA, Frederick WR, et al. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Intern Med 1984;101:478-83.
78. Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 1998;17:200-6.
79. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K. Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis 1990;12(Suppl 7):S827-38.
80. Plotkin SA, Smiley ML, Friedman HM, et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1984;1:528-30.
81. Suwansirikul S, Rao N, Dowling JN, Ho M. Primary and secondary cytomegalovirus infection. Arch Intern Med 1977; 137:1026-9.
82. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann Intern Med. 1991;114: 525-31.
83. Balfour HH. Prevention of cytomegalovirus disease in renal allograft recipients. Scand J Infect Dis 1991;78:88-93.
84. Plotkin SA, Higgins R, Kurtz JB. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994;58:1176-8.
85. Plotkin SA, Huang ES. Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 1985; 152:395-7.
86. Pass RF, Hutto C, Ricks R, Cloud GA. Increased rate of cytomegalovirus infection among parents of children attending day-care centers. N Engl J Med 1986;314:1414-8.
87. Adler SP. Molecular epidemiology of cytomegalovirus: evidence for viral transmission to parents from children infected at a day care center. Pediatr Infect Dis 1986;5:315-8.
88. Wang JB, Adler SP, Hempfling S, et al. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J Infect Dis 1996;174:387-92.
89. Adler SP, Hempfling SH, Starr SE, Plotkin S, Riddell S. Evaluation of the safety and immunogenicity of the Towne strain of cytomegalovirus among women of childbearing age and children. Pediatr Infect Dis 1998;17:200-6.
90. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 1996;70:78-83.
91. Mocarski ES Jr, Kemble GW. Recombinant cytomegaloviruses for study of replication and pathogenesis. Intervirology 1996;39:320-30.
92. Qadri I, Navarro D, Paz P, Pereira L. Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus. J Gen Virol 1992;73:2913-21.
93. Gonczol E, Ianocone J, Ho WZ, et al. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 1990;8:130-6.
94. Spaete RR. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 1991;23:90-6.
95. Burke RL. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. J Infect Dis 1991;13:S906-11.
96. Mitchell D, Holmes SJ, Burke RL, et al. Immunogenicity of a recombinant human cytomegalovirus (CMV) gB vaccine in toddlers [Abstract]. Presented at the Sixth International Cytomegalovirus Workshop, Perdido Beach, AL, March 5 to 9, 1997.
97. Adler SP. Current prospects for immunization against cytomegaloviral disease. Infect Agents Dis 1996;5:29-35.
98. Liu H, Chou S, Sekulovich R, et al. A CMV glycoprotein gB subunit vaccine elicits cross neutralizing antibodies that cross neutralize clinical isolates [Abstract 43]. Presented at the Sixth International Cytomegalovirus Workshop, Perdido Beach, AL, March 5 to 9, 1997.
99. Pass R, Duliège AM, Sekulovich R, et al. Antibody response to a fourth dose of CMV gB vaccine in healthy adults [Abstract 159]. Presented at the Sixth International Cytomegalovirus Workshop, Perdido Beach, AL, March 5 to 9, 1997.
100. Urban M, Klein M, Britt WJ, et al. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 1996;77:1537-47.
101. Rasmussen L, Morris S, Wolitz R, et al. Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. J Infect Dis 1994;170: 673-7.
102. Keay S, Baldwin B. Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment. J Virol 1991;65:5124-8.
103. Bennink JR, Yewdell JW, Smith GL, et al. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 1984;311:578-9.
104. Henderson DA, Moss B. Smallpox. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: Saunders, 1999.
105. Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 1982;79:4927-31.
106. Magno A., Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 1982;79:7415-9.
107. Sutter G, Wyatt LS, Foley P, et al. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994;12:1032-40.
108. Taylor J, Meignier B, Tartaglia J, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 1995;13: 539-49.
109. Plotkin SA, Cadoz M, Meignier B, et al. The safety and use of canarypox vectored vaccines. Dev Biol Stand 1995;84: 165-70.
110. Fries LF, Tartaglia J, Taylor J, et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996;14:428-34.
111. Excler JL, Plotkin SA. The prime-boost concept applied to HIV preventive vaccines. AIDS 1997;11:S127-37.
112. Gonczol E, Berencsi K, Pincus S, et al. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 1995;13:1080-5.
113. Adler SP, Plotkin SA, Gonczol E, et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis (in press).
114. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-79.
115. McLaughlin-Taylor E, Pande H, Forman SJ, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994;43:103-10.
116. Burian K, Endresz V, Gyulai Z, et al. Prevalence of the IE1-exon4-specific CTL in naturally seropositive healthy individuals [Abstract]. Presented at the Seventh International Cytomegalovirus Workshop, Brighton, UK, March 7 to 9, 1999.
117. Gyulai Z, Pincus S, Cox B, et al. Canarypox-CMV-pp65 recombinant immunization of seronegative subjects elicits pp65 specific CTL precursors with a frequency comparable to pp65 specific frequency of naturally seropositive individuals [Abstract]. Presented at the Seventh International Cytomegalovirus Workshop, Brighton, UK, March 7 to 9, 1999.
118. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8.
119. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9.
120. Endresz V, Kari L, Berencsi K, et al. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphorprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 1999;17:50-8.
121. Pande H, Campo K, Tanamachi B, et al. Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Scand J Infect Dis 1998;Suppl 99:117-20.
122. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997;90:1751-67.
123. Stagno S, Reynolds DW, Huang ES, et al. Congenital cytomegalovirus infection. N Engl J Med 1977;296:1254-8.
124. Krech U, Konjajev Z, Jung M. Congenital cytomegalovirus infection in siblings from consecutive pregnancies. Helv Paediatr Acta 1971;26:355-62.
125. Lucht E, Brytting M, Bjerregaard L, et al. Shedding of cytomegalovirus and herpesviruses 6, 7, and 8 in saliva of human immunodeficiency virus type 1-infected patients and healthy controls. Clin Infect Dis 1998;27:137-41.
126. Fox JC, Kidd IM, Griffiths PD, et al. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. J Gen Virol 1995;76:309-19.
127. Melnick JL, Adam E, DeBakey ME. Cytomegalovirus and atherosclerosis. BioEssays 1995;17:899-903.
128. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-6.
129. Lowry RW, Adam E, Hu C. What are the implications of cardiac infection with cytomegalovirus before heart transplantation. J Heart Lung Transplant 1994;13:122-8.
130. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-6.
131. Loebe M, Schuler S, Zais O, et al. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant 1990;9:707-11.
132. Zhou YF, Leon MB, Waclawiwq MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 35:624-30.
133. Muganda P, Mendoza O, Hernandez J, Qian Q. Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts. J Virol 1994;68:8028-34.
134. Speir E, Modali R, Huang ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391-4.
135. Wu TC, Hruban RH, Ambinder RF. Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts. Am J Pathol 1992;140:739-45.
136. Melnick JL, Hu C, Burek J, et al. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol 1994;42:170-4.
137. Berencsi K, Endresz V, Klurfeld D, et al. Early atherosclerotic plaques in the aorta following cytomegalovirus infection of mice. Cell Adhes Commun 1998;5:39-47.
138. Sinzger C, Jahn G. Human cytomegalovirus cell tropism and pathogenesis. Intervirology 1996;39:302-19.
139. Porath A, McNutt RA, Smiley LM, Weigle KA. Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Rev Infect Dis 1990;12:31-40.
140. Rosenthal S, Stanberry LR, Biro FM, et al. Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis 1997;24:135-9.
141. Gratacap-Cavallier B, Bosson JL, Morarnd P, et al. Cytomegalovirus seroprevalence in French pregnant women. Eur J Epidemiol 1998;14:147-52.